Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases

  • 258 Accesses

  • 69 Citations

Abstract

The aim of this study was to evaluate the incidence of neurological manifestations of Behçet's disease (BD) in patients on cyclosporin A (CSA) compared with those on other medications. The records of 117 patients with BD who visited our hospital between 1990 and 2003 were reviewed with respect to symptoms and medication. All episodes of constant therapy prior to central nervous system (CNS) involvement were counted, and then the associations were analysed by the exact Fisher–Freeman–Halton test and adjusted for multiple tests by the Bonferroni–Holm method. We observed ten new cases of CNS manifestations in our patients with BD being regularly seen and treated in our tertiary care centre. The overall prevalence of neuro-BD in our patient group was 8.5%. In a retrospective analysis, the incidence of new-onset neurological disease (neuro-BD) in all patients with BD who regularly visited our hospital was significantly higher in patients on CSA than in those on other medications (6 of 21 vs 0 of 175 episodes, P<0.0001). This contrasts the obvious efficacy of CSA on extracerebral manifestations of BD, such as severe ocular disease, mucocutaneous lesions or arthritis. CSA exerts differential efficacy on various manifestations of BD. It is very effective for severe ocular and other moderate to severe manifestations of BD, but its efficacy for the prevention of neuro-BD seems to be inferior to that of other medications used in BD, such as azathioprine or interferon-α. The reasons for this are unclear, but the potential toxic effects of CSA on the CNS may be a predisposing factor for CNS vasculitis in BD.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    International Study Group for Behcet's Disease (1990) Criteria for diagnosis of Behcet's disease. Lancet 335:1078–1080

  2. 2.

    Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behcet's syndrome. Brain 122(Pt 11):2183–2194

  3. 3.

    Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 122(Pt 11):2171–2182

  4. 4.

    Siva A, Kantarci OH, Saip S, et al (2001) Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95–103

  5. 5.

    Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcet's disease—an overview. In: Lehner T, Barnes CG (eds) Recent advances in Behçet's disease. Royal Society of Medicine Services, London, pp 177–180

  6. 6.

    Krause I, Rosen Y, Kaplan I, et al (1999) Recurrent aphthous stomatitis in Behcet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 28:193–196

  7. 7.

    Kotter I, Vonthein R, Muller CA, Gunaydin I, Zierhut M, Stubiger N (2004) Behcet's disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol 31:133–139

  8. 8.

    Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2000) Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2:CD001084

  9. 9.

    Hinchey J, Chaves C, Appignani B, et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500

  10. 10.

    Gijtenbeek JMM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246:339–346

  11. 11.

    Filley CM, Kleinschmidt-DeMasters BK (2001) Toxic leukoencephalopathy. N Engl J Med 345:425–432

  12. 12.

    Lee SH, Yoon PH, Park SJ, Kim DI (2001) MRI findings in neuro-Behçet's disease. Clin Radiol 56:485–494

  13. 13.

    Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y (2001) Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 29:335–336

  14. 14.

    Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106:586–589

  15. 15.

    Meusser S, Eger G, Anders M, Burkhardt H, Kalden JR (1997) Manifestation of neuro-Behcet disease in cyclosporin A therapy. Z Rheumatol 56:31–39

  16. 16.

    Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002) Neurological manifestations of Behcet's disease in a Caribbean population: clinical and imaging findings. J Neurol 249:410–418

  17. 17.

    Serdaroglu P (1998) Behcet's disease and the nervous system. J Neurol 245:197–205

  18. 18.

    McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood–brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 58:548–554

  19. 19.

    Motomura S, Tabira T, Kuroiwa Y (1980) A clinical comparative study of multiple sclerosis and neuro-Behcet's syndrome. J Neurol Neurosurg Psychiatry 43:210–213

  20. 20.

    Krause I, Leibovici L, Guedj D, Molad Y, Uziel Y, Weinberger A (1999) Disease patterns of patients with Behcet's disease demonstrated by factor analysis. Clin Exp Rheumatol 17:347–350

  21. 21.

    Yurdakul S, Mat C, Tuzun Y, et al (2001) A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44:2686–2692

  22. 22.

    Hamuryudan V, Mat C, Saip S, et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450

  23. 23.

    Kotter I, Vonthein R, Zierhut M, et al (2004) Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 33:311–319

Download references

Acknowledgements

We thank Prof. Hasan Yazici for his critical review of the manuscript, and Prof. CA Mueller for the human leukocyte antigen (HLA) analyses.

Author information

Correspondence to Ina Kötter.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kötter, I., Günaydin, I., Batra, M. et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases. Clin Rheumatol 25, 482–486 (2006). https://doi.org/10.1007/s10067-005-0070-8

Download citation

Keywords

  • Behçet's disease
  • CNS manifestations
  • CSA